Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

Prescribed List (Jersey): Changes from 6 December 2019

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made on 6 December 2019

Decision Reference:  MD-S-2019-0097

Decision Summary Title :

DS Prescribed list as of 6 Dec 2019

Date of Decision Summary:

3 December 2019

Decision Summary Author:

Policy Principal

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

NA

Written Report

Title :

WR report PBAC 27 November 2019

Date of Written Report:

27 November 2019

Written Report Author:

Prescribing Advisor

Written Report :

Public or Exempt?

 

Public

Subject: Changes to be made to the Prescribed List (Jersey) as of 6 December 2019

Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 6 December 2019 as set out in the accompanying report and supporting document.

Reason(s) for Decision: The Pharmaceutical Benefit Advisory Committee met virtually to consider an urgent application for a new item to be added to the Prescribed List. Using its agreed procedure, members were consulted by email and their responses collated on 27 November 2019 to provide the Minister with a recommendation regarding an amendment to the Prescribed List.

 

Item to be added to the Prescribed List: Ticagrelor 60mg tablets

 

The recommendation reflects current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs and community prescribers at a proportionate cost to the Fund.

 

Resource Implications: The overall financial impact of the above changes is expected to be a small increase in total annual expenditure of up to £5,000. 

 

Action required: Health Zone Manager at Customer and Local Services to issue a public notice listing amendments and notify all approved medical practitioners and approved contractors.

Signature:

 

 

Position:

Minister

 

Date Signed:

 

 

Date of Decision (If different from Date Signed):

 

Prescribed List (Jersey): Changes from 6 December 2019

RECOMMENDATIONS OF THE

PHARMACEUTICAL BENEFIT ADVISORY COMMITTEE

 

27 November 2019

 

Summary

 

The Pharmaceutical Benefit Advisory Committee (PBAC) was asked to consider one application for a change to the Prescribed List. In view of the clinical urgency, the Chair agreed to consult with members via email. The Committee was unanimous in its recommendation for the following change to the Prescribed List.

 

  1. Items to be added to the Prescribed List
    1. Ticagrelor 60mg tablets

 

Financial impact

 

The overall financial impact of the above change is expected to be a small increase in annual expenditure of up to £5,000.

 

Mrs Alison Creed

Chair, PBAC

 

27 November 2019

 


Recommendations

 

  1. Item to be added to the Prescribed List
    1. Ticagrelor 60mg tablets
  • Ticagrelor is currently included in the Prescribed List for the 90mg strength only. However, a 60mg strength tablet is available and recommended for use after the patient has taken the 90mg strength for 12 months. There are currently around 100 patients in Jersey currently taking the 90mg strength, some of whom need to be now switched to the lower strength.
  • Ticagrelor 60mg tablets are licensed for “the prevention of atherothrombotic events in adult patients with a history of myocardial infarction of at least 1 year and a high risk of developing an atherothrombotic event”. Use of this strength of ticagrelor for up to 3 years is supported by NICE. 

Estimated cost impact of PBAC recommendations 27 November 2019

Recommended product

Estimated cost impact

1.1  Ticagrelor 60mg tablets

Increase in total annual expenditure of up to £5,000

 

1

 

Back to top
rating button